Workflow
Seed of collaboration ties Linyi, West Africa
Globenewswire· 2025-11-24 11:06
Core Insights - Linyi Trade City from Shandong province hosted a successful quality product expo in Ghana, leading to agreements worth 16.8 million yuan ($2.36 million) with five local enterprises [1] - The expo showcased a variety of building materials and products that cater to the needs of the Ghanaian market, attracting buyers from neighboring countries due to their high quality and affordability [2] - The event highlighted the potential for Linyi's products to fill gaps in the local market, particularly in the chemical products sector, which is currently inefficient in Ghana [3] Market Potential - The Linyi merchant delegation explored Accra and Tema, identifying opportunities for establishing overseas warehouses and integrating supply chains, indicating significant investment potential [4] - The delegation's visit to the Jinyi Industrial Park reinforced confidence in Linyi's expansion into West Africa, with local officials expressing eagerness for investment and collaboration [5] - Accra's government is prepared to assist Linyi enterprises in expanding their market presence, emphasizing a strong partnership [6]
Scilex Holding Company Announces Exercise of Warrants for $20.3 Million Gross Proceeds
Globenewswire· 2025-11-24 11:00
Core Viewpoint - Scilex Holding Company has entered into a definitive agreement to exercise existing warrants, which is expected to generate approximately $20.3 million in gross proceeds for the company [1][4]. Group 1: Existing Warrants - The company will exercise a total of 428,572 shares from April 2024 Warrants at an exercise price of $38.50 per share and 475,824 shares from December 2024 Warrants at an exercise price of $22.72 per share [1]. - The aggregate gross proceeds from the exercise of these existing warrants are anticipated to be around $20.3 million before deducting fees and expenses [1]. Group 2: New Warrant Issuance - In exchange for the immediate cash exercise of the existing warrants, the company will issue a new unregistered warrant to purchase up to 1,356,594 shares of common stock at an exercise price of $29.00 per share [3]. - The new warrant will be exercisable immediately upon issuance and will have a term of five years [3]. Group 3: Use of Proceeds - The net proceeds from the offering are expected to be utilized for working capital and general corporate purposes [4]. Group 4: Company Overview - Scilex is focused on acquiring, developing, and commercializing non-opioid pain management products for treating acute and chronic pain, as well as neurodegenerative and cardiometabolic diseases [7][8]. - The company's commercial products include ZTlido, ELYXYB, and Gloperba, which target significant unmet medical needs [8][9].
Rakovina Therapeutics Inc. Announces Presentation of Second Abstract at the 2025 Society for Neuro-Oncology Annual Meeting
Globenewswire· 2025-11-24 11:00
Core Insights - Rakovina Therapeutics is advancing its AI-derived PARP-1 inhibitor program, showcasing progress at the 2025 Society for Neuro-Oncology Annual Meeting [1][5] - The company is utilizing AI methods to discover and characterize novel PARP1-selective small-molecule drug candidates that penetrate the central nervous system (CNS) [2][4] Research and Development - A scientific poster titled "Discovery and development of novel CNS-penetrating PARP1-selective inhibitors" was presented, highlighting collaboration with the Vancouver Prostate Centre and the University of British Columbia [2] - The research employs Deep Docking™ and generative-AI computational approaches to screen large chemical libraries for compounds with selective inhibition of PARP1 and favorable drug-like properties [3][4] Results and Data - Hundreds of prioritized compounds have been synthesized and evaluated, with a subset showing PARP1-selective activity and promising in vitro metabolic stability and pharmacokinetic profiles [4] - The presentation included comparisons of ADME and pharmacokinetic data from synthesized compounds against existing PARP inhibitors and next-generation benchmarks [4] Company Overview - Rakovina Therapeutics focuses on innovative cancer treatments, leveraging AI technologies like Deep-Docking™ and Enki™ to enhance drug candidate optimization [6] - The company aims to advance its pipeline of DNA-damage response inhibitors into human clinical trials in collaboration with pharmaceutical partners [7]
Coppernico Files Expanded Drill Permit at its Copper-Gold Sombrero Project in Peru
Globenewswire· 2025-11-24 11:00
VANCOUVER, British Columbia, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Coppernico Metals Inc. (TSX: COPR, OTCQB: CPPMF, FSE: 9I3) (“Coppernico” or the “Company”), through its wholly owned private Peruvian subsidiary, Sombrero Minerales SAC, is pleased to announce that, having completed all required environmental studies, it has formally submitted an Environmental Impact Assessment – Semi-detailed ("EIA-Sd") drill permit application (the "Application") for its Sombrero Project in Peru. The permit, once granted, will ...
Enerflex Ltd. Announces the Appointment of Céline Gerson as New Independent Director
Globenewswire· 2025-11-24 11:00
Core Insights - Enerflex Ltd. has appointed Ms. Céline Gerson to its Board of Directors, effective immediately [1] - Ms. Gerson brings 25 years of experience from Fortune 500 companies, enhancing the Board's skillset as Enerflex pursues its strategic goals [2] - Ms. Gerson expressed her enthusiasm for joining Enerflex at a pivotal time, emphasizing the company's commitment to sustainable shareholder value [3] About Céline Gerson - Ms. Gerson has a strong background in international business, strategy development, and commercial positioning, currently serving as President and Group Director for Fugro Americas [3][4] - She holds a B.B.A in International Finance and Marketing and a J.D., along with an Executive Leadership Development program from Harvard Business School [4] About Enerflex - Enerflex is a global provider of energy infrastructure and transition solutions, focusing on natural gas and sustainability [5] - The company employs over 4,400 professionals dedicated to transforming energy for a sustainable future [5] - Enerflex's shares are traded on the Toronto Stock Exchange and the New York Stock Exchange under the symbols "EFX" and "EFXT," respectively [6]
Mike Lindell Media Corp. (MLMC) and LindellTV Announce New Chief Pentagon Reporter
Globenewswire· 2025-11-24 11:00
Core Points - Mike Lindell Media Corp. has recruited Heather Mullins as the Chief Pentagon Correspondent, enhancing its news division [1][3] - Mullins has a strong military background and extensive experience in election integrity reporting, which aligns with the company's focus [2][3] - The company aims to provide unbiased coverage from the Pentagon, alongside its existing reporting from the White House and Capitol Hill [3][4] Company Overview - Mike Lindell Media Corp. operates a conservative broadcast network, providing an alternative to mainstream media through its platforms, LindellTV and VOCL [4] - The company has grown to serve over 7 million monthly viewers and has recently gained press access to White House events [4] - LindellTV was rebranded from frankspeech.com in February 2025, and VOCL was rebranded from FrankSocial in September 2024 [4] Personnel and Expertise - Heather Mullins has a background in investigative journalism, particularly in election integrity, and has previously contributed to various media outlets [3] - Mullins expressed her honor in joining LindellTV, emphasizing her commitment to serving the military and the country through journalism [2][3] - Mike Lindell, the CEO, highlighted Mullins as a tremendous asset to the company, expecting her to deliver significant stories from the Pentagon [3]
RecycLiCo Retains Retiring Director Andris Kikauka as Consultant to Support Legacy Mining Asset Management
Globenewswire· 2025-11-24 11:00
Core Insights - RecycLiCo Battery Materials Inc. announced the retirement of Andris Kikauka from its Board of Directors, who will continue as a consultant to support the management of the company's legacy mining assets [1][2][3] - Mr. Kikauka's consulting role will involve day-to-day advisory responsibilities, ensuring continuity in oversight, regulatory compliance, and strategic planning for the mining portfolio [2] - The company emphasizes the importance of Mr. Kikauka's experience and institutional knowledge as it advances the commercialization of its critical materials recovery technologies [2][3] Company Overview - RecycLiCo specializes in critical minerals refining and lithium-ion battery upcycling, utilizing advanced hydrometallurgical technologies to process mined ore and recover materials [4] - The company's processes efficiently recover battery-ready lithium, cobalt, nickel, and manganese from end-of-life batteries and manufacturing scrap, supporting energy storage and industrial applications [4] - RecycLiCo's business aligns with the global demand for responsible supply chains and the movement towards strengthening domestic sourcing of critical materials [4]
Alvotech Announces Approval of AVT03, a Biosimilar to Prolia® and Xgeva® (denosumab) in the European Economic Area
Globenewswire· 2025-11-24 10:30
Core Viewpoint - Alvotech has received approval from the European Commission for AVT03 as a biosimilar to Prolia and Xgeva, which is expected to enhance access to treatments for osteoporosis and cancer-related skeletal issues in Europe [1][4][5]. Company Summary - Alvotech is a global biotech company focused on developing and manufacturing biosimilar medicines, aiming to be a leader in the biosimilar space by providing high-quality, cost-effective products [11]. - The approval of AVT03 reflects Alvotech's strong end-to-end platform and its commitment to delivering affordable medicines to patients [4][5]. - Alvotech has established strategic partnerships for the commercialization of AVT03 in Europe, collaborating with STADA and Dr. Reddy's, each holding semi-exclusive rights in various regions [7][12]. Product Summary - AVT03 is approved in two forms: as a 60 mg/mL single-use pre-filled syringe for osteoporosis treatment and as a 70 mg/mL single-use vial for preventing skeletal-related events in cancer patients [3][9]. - The European denosumab market is valued at approximately US$1.2 billion, indicating a significant opportunity for AVT03 to capture market share [2]. - The approval was based on comprehensive evidence, including pharmacokinetic and pharmacodynamic data, and clinical studies demonstrating equivalent efficacy and safety compared to the reference products [8]. Market Context - Osteoporosis-related disabilities in Europe surpass those caused by common cancers, highlighting the importance of effective treatments [6]. - The economic burden of fragility fractures in Europe was estimated at €57 billion in 2019, underscoring the need for cost-effective treatment options like biosimilars [6][7].
OVHcloud and LCH SA sign cloud agreement
Globenewswire· 2025-11-24 10:10
Core Insights - OVHcloud has signed a cloud hosting agreement with LCH SA to enhance operational resilience, security, scalability, and faster deployment of services [1][2] - The migration of LCH SA's services to a SecNumCloud qualified environment marks a significant step in its digital transformation [2] - OVHcloud's SecNumCloud solution allows LCH SA to utilize advanced cloud technology while ensuring high security and regulatory compliance [3] Company Overview - OVHcloud is recognized as a global cloud player and the leader in the European cloud market [1] - LCH SA is a key provider of market infrastructure in Europe and plays a significant role in the global financial community [3] Strategic Implications - The collaboration supports LCH SA's fast-growing, diversified global activities across various asset classes [2] - The use of OVHcloud's services is expected to enhance operational efficiency and scalability for LCH SA [3]
Lotus Technology Reports Unaudited Third Quarter and First Nine Months 2025 Financial Results
Globenewswire· 2025-11-24 10:00
Core Insights - Lotus Technology Inc. reported its unaudited financial results for Q3 and the first nine months of 2025, highlighting a challenging transitional period impacted by tariffs and inventory adjustments [1][2][3] Operating Highlights - Total deliveries for the first nine months of 2025 reached 4,612 units, a significant decrease of 40% compared to 7,673 units in the same period of 2024 [5] - Deliveries were primarily driven by China and Europe, with China outpacing the premium auto segment, indicating strong competitive positioning [3][6] - The gross margin improved to 8% in Q3 2025, up from 3% in Q3 2024, attributed to a higher share of upgraded models in total deliveries [3][15] Financial Performance - Total revenue for the first nine months of 2025 was $356 million, down 46% from $653 million in the same period of 2024 [9] - The net loss narrowed by approximately 68% in Q3 and 43% for the nine-month period, indicating improved financial health [8][13] - Key financial results for Q3 2025 included revenue of $137 million, a 46% decrease year-over-year, and a net loss of $65 million, a 68% reduction from the previous year [20][15] Model and Regional Deliveries - Deliveries by model type showed a decline in both Lifestyle SUVs and Sedans (down 18%) and Sportscars (down 64%) compared to the previous year [5] - Regional delivery breakdown indicated that China accounted for 46% of total deliveries, while Europe contributed 34% [6] Strategic Developments - The company plans to unveil a new PHEV model soon, which will enhance its electrification strategy and cater to diverse consumer demands [4][11] - The strategic acquisition of Lotus UK is progressing, expected to close in 2026, aimed at integrating operations and enhancing efficiency [6][11]